Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 7,627 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Overweight, Obesity
Interventions: Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 56 more

Conditions: ADHD
Interventions: Atomoxetine Hydrochloride, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 19
States / cities: Lafayette, California • Spring Valley, California • Farmington, Connecticut + 16 more

Conditions: Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions: Carboplatin, Cisplatin, Doxorubicin Hydrochloride, Filgrastim, Laboratory Biomarker Analysis, Paclitaxel, Pegfilgrastim, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 1,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 631
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 408 more

Conditions: Opioid Dependence
Interventions: Probuphine, placebo; Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 18
States / cities: Los Angeles, California • National City, California • Oceanside, California + 14 more

Conditions: Rhabdomyosarcoma, Melanoma
Interventions: Tc99m tilmanocept, Vital Blue Dye (optional), Lymph Node Mapping; Drug · Procedure
Lead sponsor: Cardinal Health 414, LLC; Industry
Eligibility: Up to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Jacksonville, Florida • Orlando, Florida • Cincinnati, Ohio + 3 more

Conditions: Alzheimer Disease
Interventions: lecozotan SR, Donepezil; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 31 more

Conditions: Rheumatoid Arthritis
Interventions: CP-690,550, Atorvastatin, Atorvastatin Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 10
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 7 more

Conditions: Hypertension
Interventions: Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 74
States / cities: Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more

Conditions: Bipolar Disorder
Interventions: Placebo, Geodon (Ziprasidone); Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 43
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 39 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin icodec, Insulin glargine, Insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 103
States / cities: Cullman, Alabama • Concord, California • Escondido, California + 85 more

Conditions: Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
Interventions: Lenbelintide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Escondido, California • Lincoln, California • Walnut Creek, California + 19 more

Conditions: Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
Interventions: Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 124
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more

Conditions: Arthroplasty, Replacement, Hip
Interventions: Trident II Tritanium Acetabular Shell; Device
Lead sponsor: Stryker Orthopaedics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 9
States / cities: Tucson, Arizona • Jacksonville, Florida • Des Plaines, Illinois + 5 more

Conditions: Ulcerative Colitis
Interventions: OPC-6535, Asacol®; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 26
States / cities: Huntsville, Alabama • Los Angeles, California • Hollywood, Florida + 23 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone furoate/vilanterol, fluticasone furoate, vilanterol, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 16,568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 506
States / cities: Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 369 more

Conditions: Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
Interventions: Biospecimen Collection, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Stereotactic Radiosurgery; Procedure · Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 29
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 23 more

Conditions: Psoriasis
Interventions: Tacrolimus Cream; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 12 Years and older
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 31
States / cities: Birmingham, Alabama • Fresno, California • Santa Monica, California + 26 more

Conditions: Hypertension
Interventions: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 39
States / cities: Foley, Alabama • Carmichael, California • Los Angeles, California + 33 more

Conditions: Intracranial Aneurysm
Interventions: Next Generation Neuroform Stent System; Device
Lead sponsor: Stryker Neurovascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 25
States / cities: Los Angeles, California • Thousand Oaks, California • Englewood, Colorado + 20 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Insulin like growth factor, type 1, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 19
States / cities: Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 16 more

Conditions: Spinal Duraplasty
Interventions: Adherus Dural Sealant System, DuraSeal Exact Dural Sealant System; Device
Lead sponsor: Stryker Craniomaxillofacial; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 14
States / cities: Duarte, California • Sacramento, California • Stanford, California + 9 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Albiglutide (GSK716155) or exenatide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 158
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 142 more

Conditions: Rheumatoid Arthritis
Interventions: etanercept, Placebo, DMARD Therapy; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 38
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more

Conditions: Multiple Myeloma
Interventions: Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib; Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 46
States / cities: Gilbert, Arizona • Duarte, California • Los Angeles, California + 35 more

Search by objective public record fields.

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Trident II Tritanium Acetabular Shell Outcomes Study

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis

Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Neuroform Atlas Stent System Study

Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial

Adherus™ Dural Sealant in Spinal Procedures

Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only

Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma